Summary
Current clinical medicine relies on MRI and CT for structural imaging, and immuno-PET/SPECT for molecular specificity. The combination of structural imaging and molecular specific imaging provides detailed information about expression of proteins and cell surface receptors in vivo in humans. PET-CT/MRI has become an essential component of personalized medicine. However, the resolution of MRI/CT is just under a millimeter, while the resolution of PET is limited to about 2-10 millimeters, insufficient for early disease detection. Moreover, PET is associated with radiation burden of ligands labeled with a radiotracer and can image only one labeled ligand at a time.
What is missing is the ability to image in vivo with much higher resolution, and to image multiple molecular targets and molecular interactions simultaneously. I propose to develop the optical equivalent of PET- CT/MRI with a 10 to 100 fold better resolution. To reach this goal I will integrate three-dimensional endoscopic Optical Coherence Tomography (OCT) for structural information with depth resolved imaging of fluorescently labeled monoclonal antibodies for molecular specificity.
To image the hollow organs accessible by endoscopy, I will develop the immuno-OCT technology integrated with miniature motorized catheters and the multi-fiber detection technology for depth resolved fluorescence determination for endoscopic immuno-OCT in catheters as small as 1.5 mm diameter. I will focus on esophageal cancer and lung disease. The proposed research has a much broader impact, creating a platform to study in detail therapy-tissue interactions longitudinally in vivo in patients, providing in vivo information approaching immunohistochemistry analysis. This approach will revolutionize the diagnosis and treatment of patients with a resolution approaching immunohistology at high speed over large volumes using minimally invasive technologies.
What is missing is the ability to image in vivo with much higher resolution, and to image multiple molecular targets and molecular interactions simultaneously. I propose to develop the optical equivalent of PET- CT/MRI with a 10 to 100 fold better resolution. To reach this goal I will integrate three-dimensional endoscopic Optical Coherence Tomography (OCT) for structural information with depth resolved imaging of fluorescently labeled monoclonal antibodies for molecular specificity.
To image the hollow organs accessible by endoscopy, I will develop the immuno-OCT technology integrated with miniature motorized catheters and the multi-fiber detection technology for depth resolved fluorescence determination for endoscopic immuno-OCT in catheters as small as 1.5 mm diameter. I will focus on esophageal cancer and lung disease. The proposed research has a much broader impact, creating a platform to study in detail therapy-tissue interactions longitudinally in vivo in patients, providing in vivo information approaching immunohistochemistry analysis. This approach will revolutionize the diagnosis and treatment of patients with a resolution approaching immunohistology at high speed over large volumes using minimally invasive technologies.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101141674 |
| Start date: | 01-01-2025 |
| End date: | 31-12-2029 |
| Total budget - Public funding: | 2 500 000,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Current clinical medicine relies on MRI and CT for structural imaging, and immuno-PET/SPECT for molecular specificity. The combination of structural imaging and molecular specific imaging provides detailed information about expression of proteins and cell surface receptors in vivo in humans. PET-CT/MRI has become an essential component of personalized medicine. However, the resolution of MRI/CT is just under a millimeter, while the resolution of PET is limited to about 2-10 millimeters, insufficient for early disease detection. Moreover, PET is associated with radiation burden of ligands labeled with a radiotracer and can image only one labeled ligand at a time.What is missing is the ability to image in vivo with much higher resolution, and to image multiple molecular targets and molecular interactions simultaneously. I propose to develop the optical equivalent of PET- CT/MRI with a 10 to 100 fold better resolution. To reach this goal I will integrate three-dimensional endoscopic Optical Coherence Tomography (OCT) for structural information with depth resolved imaging of fluorescently labeled monoclonal antibodies for molecular specificity.
To image the hollow organs accessible by endoscopy, I will develop the immuno-OCT technology integrated with miniature motorized catheters and the multi-fiber detection technology for depth resolved fluorescence determination for endoscopic immuno-OCT in catheters as small as 1.5 mm diameter. I will focus on esophageal cancer and lung disease. The proposed research has a much broader impact, creating a platform to study in detail therapy-tissue interactions longitudinally in vivo in patients, providing in vivo information approaching immunohistochemistry analysis. This approach will revolutionize the diagnosis and treatment of patients with a resolution approaching immunohistology at high speed over large volumes using minimally invasive technologies.
Status
SIGNEDCall topic
ERC-2023-ADGUpdate Date
03-10-2024
Images
No images available.
Geographical location(s)
